<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04597944</url>
  </required_header>
  <id_info>
    <org_study_id>38RC20.187</org_study_id>
    <secondary_id>2020-A01528-31</secondary_id>
    <nct_id>NCT04597944</nct_id>
  </id_info>
  <brief_title>Lanadelumab in Bradykinin Angioedema</brief_title>
  <acronym>KALAN</acronym>
  <official_title>Evaluation of the Efficacy of Kallikrein Inhibition by Lanadelumab for Patients With Bradykinin Angioedema: a Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter observational study aiming to evaluate the efficacy of kallikrein inhibition by&#xD;
      lanadelumab in patients with bradykinin- angioedema&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The bradykinin-angioedema (AE-BK) is characterized by recurrent and unpredictable episodes of&#xD;
      swelling; it can be disabling and disfiguring and the attacks affecting the larynx can be&#xD;
      life-threatening.&#xD;
&#xD;
      The clinical symptoms depend on accumulation of bradykinin (BK), a vasoactive peptide&#xD;
      responsible for vasodilation and increase of vascular leakage. BK formation depends on&#xD;
      activation of the kallikrein-kinin cascade leading to uncontrolled generation of plasma&#xD;
      kallikrein and subsequent proteolysis of high molecular-weight kininogen (HK).&#xD;
&#xD;
      Lanadelumab is a fully human monoclonal antibody inhibitor of plasma kallikrein, thereby&#xD;
      preventing BK production; it represents an attractive therapeutic strategy for BK-AE&#xD;
      prophylaxis.&#xD;
&#xD;
      The aim of this study is to evaluate the kallikrein inhibition by assessing the levels of&#xD;
      cleaved HK and the immunogenicity of the lanadelumab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2020</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Evaluation of the efficacy of the kallikrein inhibition by lanadelumab in patients with bradykinin-angioedema</measure>
    <time_frame>3 months</time_frame>
    <description>Levels of cleaved HK measured by Western Blot</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the efficacy of kallikrein inhibition by lanadelumab in patients with bradykinin-angioedema between T0 and the others visits</measure>
    <time_frame>Day 7; 6, 12 and if possible 24 months</time_frame>
    <description>Levels of cleaved HK as measured by Western Blot Ratio Day 7/ Day 0, Ratio Month 6/ Day 0, Ratio Month 12/ Day (and if possible Month 24/ Day 0) of the levels of cleaved HK as measured by Western Blot&#xD;
- SE2: antidrug antibodies in the sera of patients at Months 3, 6, 12 (and if possible Month 24).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of lanadelumab</measure>
    <time_frame>Months 3, 6, 12 (and 24 if possible)</time_frame>
    <description>Levels of antidrug antibodies in the sera of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of therapeutic escape</measure>
    <time_frame>Months 3, 6, 12 and if possible 24</time_frame>
    <description>Increase/absence of decrease of the number of attacks during lanadelumab administration</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Angioedema</condition>
  <arm_group>
    <arm_group_label>Participants with Hereditary or Acquired Angioedema</arm_group_label>
    <description>Participants older than 18 years that are diagnosed with Hereditary or Acquired Angioedema and treated by lanadelumab.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hereditary or Acquired Angiodema&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male/female &gt;18 years old&#xD;
&#xD;
          -  Patient with hereditary or acquired angioedema&#xD;
&#xD;
          -  Patient treated by lanadelumab&#xD;
&#xD;
          -  Patient whose the biological explorations have been carried out or will be carried out&#xD;
             at Laboratory of Immunology of CHUGA&#xD;
&#xD;
          -  Informed consent is obtained from the participant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Absence of biological material at T0 and M3 (stored for routine analysis)&#xD;
&#xD;
          -  Person under guardianship or curatorship&#xD;
&#xD;
          -  Female who is pregnant, nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Federica Defendi, PhD</last_name>
    <phone>+330476765416</phone>
    <email>fdefendi@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charlotte Kevorkian-Verguet</last_name>
    <phone>+330476765416</phone>
    <email>ckevorkian-verguet@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérica DEFENDI</last_name>
      <phone>+33 (0)4 76 76 54 16</phone>
      <email>fdefendi@chu-grenoble.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kallikrein, Kininogen, Bradykinin, Lanadelumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

